Engineered immune cells take on rare autoimmune disease
NCT ID NCT07298590
First seen Jan 06, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This early-phase study tests a new treatment called KN5601, which uses specially engineered natural killer (NK) cells to target and destroy disease-causing immune cells in people with relapsed or refractory IgG4-related disease. The trial will enroll 18 adults and primarily check for safety and whether the disease goes into remission without needing steroids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital
Shanghai, 200433, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19/BCMA CAR-NK cells (KN5601) with chemotherapy (fludarabine and cyclophosphamide)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat IgG4-related disease, potentially reducing symptoms without long-term steroids.
What could go wrong
This is a very early, small trial (18 people) focused on safety. The treatment involves chemotherapy and cell therapy, which can cause serious side effects. It may not work or may not be better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.